1. Home
  2. CRDL vs POAS Comparison

CRDL vs POAS Comparison

Compare CRDL & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

N/A

Current Price

$6.21

Market Cap

85.9M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CRDL
POAS
Founded
2017
2017
Country
Canada
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
85.9M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
CRDL
POAS
Price
$1.07
$6.21
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
373.9K
957.4K
Earning Date
03-30-2026
02-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$128,328.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$2.90
52 Week High
$1.59
$7.40

Technical Indicators

Market Signals
Indicator
CRDL
POAS
Relative Strength Index (RSI) 57.74 71.81
Support Level $0.95 $5.86
Resistance Level $1.04 $7.40
Average True Range (ATR) 0.05 0.57
MACD 0.01 0.31
Stochastic Oscillator 76.47 72.71

Price Performance

Historical Comparison
CRDL
POAS

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

Share on Social Networks: